Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023. In the quarter to June 2026, revenue fell 57.1%, EPS grew 71.9%, free cash flow grew 25.3% and total debt rose 1.54%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow GUTS
Fractyl Health, Inc. (GUTS) EV/Sales
As of 16 October 2026, Fractyl Health, Inc. (GUTS) trades at a EV/Sales of 2,465×. Over the past ten years it has ranged from 1,494× (March 2024) to 22,318× (July 2024); the current reading is higher than 6% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | 11,173× | 287.76% |
| FY2023 | 2,881× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | 11,173× | (22.71%) |
| Sep 2024 | 14,455× | (30.89%) |
| Jun 2024 | 20,917× | 20.67% |
| Mar 2024 | 17,334× | 501.60% |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| TENX Tenax Therapeutics, Inc. compare | −142× |
| BOLD Boundless Bio, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| GOSS Gossamer Bio, Inc. compare | 4.0× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | 8.6× |
| RNXT RenovoRx, Inc. compare | 25.2× |
| GUTS Fractyl Health, Inc. | 2,465× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)